<DOC>
	<DOCNO>NCT02678156</DOCNO>
	<brief_summary>The aim Post Market Clinical Follow-up Study collect clinical data performance Lyoplant® Onlay . To assess performance product , various safety efficacy parameter select .</brief_summary>
	<brief_title>Assessment Performance LYoplant® ONlay Duraplasty</brief_title>
	<detailed_description />
	<criteria>Patients undergo elective cranial spinal surgery , probably need duraplasty use Lyoplant® Onlay Written inform consent Life expectancy &gt; 6 month Age &gt; 18 year Active local systemic infection Open cranial trauma Open spina bifida Known hypersensitivity proteins bovine origin Representation legal guardian involuntary commitment Pregnancy Participation another clinical study Known primary immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Dura mater substitute</keyword>
	<keyword>Graft</keyword>
	<keyword>Lyoplant</keyword>
	<keyword>Lyostypt</keyword>
	<keyword>Lyoplant onlay</keyword>
	<keyword>Xenograft</keyword>
</DOC>